Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 13;7:e2200421. doi: 10.1200/PO.22.00421

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 1. — Diagrams for subprotocols (A) S1 and (B) S2. ^aReasons for not receiving an assignment: study suspended (n = 15), assigned to another arm for which the qualifying variant’s level of evidence was higher (n = 7), before study activation (n = 6), assigned to another arm for which accrual was lower (n = 2), and prior treatment of trametinib (n = 1). ^bReasons not enrolled after receiving an assignment: active infection and abnormal brain MRI (n = 1), deteriorating performance status (n = 6), eye problems (n = 1), in hospice care (n = 1), inadequate organ/marrow function (n = 2), interstitial lung disease/pneumonitis (n = 2), intervening news/targeted treatment (n = 2), other investigational treatment (n = 1), patient died (n = 6), patient refusal (n = 4), receiving other therapy (n = 2), and unknown (n = 3). ^cReasons for being nonevaluable: no disease assessment done before death (n = 4), no disease assessment done before NPT (n = 1), baseline scans done outside of specified window (n = 5), withdrew consent (n = 2), different methods of evaluation used (n = 1), no evaluation during treatment (n = 1). ^dReasons for not receiving an assignment: ineligible histology—uveal melanoma (n = 13). ^eReasons not enrolled after receiving an assignment: central screening cohort: ineligible histology (n = 1), ineligible histology and inadequate organ/marrow function (n = 1), and unknown (n = 1). NPT, nonprotocol therapy.

FIG 1. — Diagrams for subprotocols (A) S1 and (B) S2. ^aReasons for not receiving an assignment: study suspended (n = 15), assigned to another arm for which the qualifying variant’s level of evidence was higher (n = 7), before study activation (n = 6), assigned to another arm for which accrual was lower (n = 2), and prior treatment of trametinib (n = 1). ^bReasons not enrolled after receiving an assignment: active infection and abnormal brain MRI (n = 1), deteriorating performance status (n = 6), eye problems (n = 1), in hospice care (n = 1), inadequate organ/marrow function (n = 2), interstitial lung disease/pneumonitis (n = 2), intervening news/targeted treatment (n = 2), other investigational treatment (n = 1), patient died (n = 6), patient refusal (n = 4), receiving other therapy (n = 2), and unknown (n = 3). ^cReasons for being nonevaluable: no disease assessment done before death (n = 4), no disease assessment done before NPT (n = 1), baseline scans done outside of specified window (n = 5), withdrew consent (n = 2), different methods of evaluation used (n = 1), no evaluation during treatment (n = 1). ^dReasons for not receiving an assignment: ineligible histology—uveal melanoma (n = 13). ^eReasons not enrolled after receiving an assignment: central screening cohort: ineligible histology (n = 1), ineligible histology and inadequate organ/marrow function (n = 1), and unknown (n = 1). NPT, nonprotocol therapy.